Gw Pharmaceuticals Plc Ads (GWPH) 121.00 $GWPH The Worst

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 11:05 AM

Gw Pharmaceuticals Plc Ads (GWPH) 121.00 $GWPH

The Worst Stocks for a Stock Market Crash
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 25, 1:04PM CDT
It's not a matter of "if" the stock market is going to crash again -- it's a matter of "when." Source: Flickr user Jedimentat44. Between 1997 and 2011 the Dow Jones Industrial Average , arguably the most followed stock market index in the...
TSLA: 218.43 (-0.17), GWPH: 121.00 (+0.23), ACI: 1.03 (+0.04), C: 52.90 (-0.32), AAL: 52.71 (+1.26)

Is It Finally Time to Invest in Marijuana?
Dan Dzombak, Dan Caplinger, and George Budwell, The Motley Fool - Motley Fool - Sat Apr 25, 9:10AM CDT
Source: Flickr user Brett Levin. As public sentiment continues to shift in favor of marijuana legalization and more states legalize medical (and in some cases even recreational) marijuana, more people than ever are wondering whether now is the time...
RAI: 76.26 (-0.71), GWPH: 121.00 (+0.23), MO: 52.07 (-0.28)

Critical Alerts For GW Pharmaceuticals, Johnson Controls, Microsoft, Petrobras and Dunkin' Brands Released By InvestorsObserver
PR Newswire - Fri Apr 24, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GWPH, JCI, MSFT, PBR and DNKN.
PBR: 9.99 (+0.59), DNKN: 54.03 (+2.52), GWPH: 121.00 (+0.23), MSFT: 47.87 (+4.53), JCI: 52.48 (-0.42)

GW Pharma's cannabidiol an Orphan Drug for newborn brain injury
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 7:29AM CDT

GWPH: 121.00 (+0.23)

GW Pharmaceuticals Receives Orphan Drug Designation From FDA for Cannabidiol for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy
GlobeNewswire - Fri Apr 24, 6:00AM CDT
GW Pharmaceuticals plc (AIM:GWP) (Nasdaq:GWPH) ("GW"

announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Cannabidiol (CBD) for use in treating newborn children with neonatal hypoxic-ischemic encephalopathy (NHIE). NHIE is acute or sub-acute brain injury due to asphyxia caused during the birth process and resulting from deprivation of oxygen during birth (hypoxia).
GWPH: 121.00 (+0.23)

GW Pharmaceuticals Announces New Physician Reports of Epidiolex(R) Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy
GlobeNewswire - Wed Apr 22, 5:15PM CDT
Conference Call Today at 6:30 p.m. ET
GWPH: 121.00 (+0.23)

Thanks, But No Thanks! 3 Wall Street "Strong Buys" We Wouldn't Touch
Sean Williams, Dan Caplinger, and George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 12:02PM CDT
Source: Flickr user snowlepard. Every day Wall Street analysts issue buy or sell ratings on companies they cover, and investors tend to eat these ratings up as Wall Street analysts are perceived to have far more knowledge in the sector they cover...
GWPH: 121.00 (+0.23), SNE: 31.34 (+0.62), VGR: 22.60 (+0.07)

Is Legalized Marijuana or Gene Therapy the Better Emerging Industry?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:59AM CDT
The ability to spot powerful new technologies or industries early on can result in eye-popping returns for investors. The brave few that initially recognized the potential of Tesla Motors ' electric car, for example, have been richly rewarded over...
BLUE: 136.26 (-3.82), TSLA: 218.43 (-0.17), QURE: 26.09 (-0.28), GWPH: 121.00 (+0.23), CLDN: 13.68 (-0.26)

GW Pharma initiates second Phase 3 study of Epidiolex in Dravet syndrome
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 10:01AM CDT

GWPH: 121.00 (+0.23)

GW Pharmaceuticals Initiates Second Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome
GlobeNewswire - Tue Apr 21, 6:00AM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"

, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that it has initiated the second Phase 3 clinical trial of Epidiolex (cannabidiol or CBD) for the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. This follows GW's recent announcement of the commencement of the first Phase 3 clinical trial of Epidiolex in Dravet syndrome. GW expects to complete patient recruitment into this second trial in 2015 and to report top-line results in early 2016.
GWPH: 121.00 (+0.23)

Big Pharma and Tobacco Companies Will Benefit From Cannabis Boom
at The Street - Mon Apr 20, 6:32PM CDT
Christian Hageseth, founder of Green Man Cannabis and author of ‘Big Weed,’ gives a glimpse into the business side of the marijuana world.
GWPH: 121.00 (+0.23)

President Obama Crushes the Marijuana Movement With 15 Words
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 19, 10:41AM CDT
Source: National Institute on Drug Abuse, Facebook. When it comes to the polarizing debate of whether or not marijuana should be decriminalized, a slight majority of the American public continues to be in favor of legalizing the drug. Gallup's...
GWPH: 121.00 (+0.23)

Does This Marijuana Drug Study Change Everything?
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 18, 12:14PM CDT
If marijuana advocates hope to win over voters in tough-to-convince states like Florida next year, they'll need more than anecdotal evidence of marijuana's medical benefits. Instead, they'll need hard science that proves marijuana's efficacy in...
GWPH: 121.00 (+0.23)

Seeking Alpha's Biotech Weekly: Celgene Check-Up, Is Gilead The New Apple?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors geared up for earnings season, highlighted several...
SGYP: 4.01 (-0.10), BIIB: 401.71 (-28.57), ARWR: 7.28 (+0.05), AMGN: 167.91 (-1.26), MYL: 76.06 (+2.37), BMY: 65.80 (-0.20), CNCE: 14.68 (-0.26), CELG: 118.71 (+2.62), ATNM: 2.95 (-0.08), PFS: 18.06 (-0.62), NVIV: 13.03 (+0.64), GILD: 103.69 (-1.52), FWP: 32.03 (-0.06), GWPH: 121.00 (+0.23), IBM: 169.78 (-0.46), BAX: 71.14 (-0.37), AZN: 71.79 (-1.34), TEVA: 64.41 (+1.16)

Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part IV
Anthony Cataldo - at Seeking Alpha - Fri Apr 17, 12:54PM CDT

FULL: 3.60 (-0.12), GWPH: 121.00 (+0.23)

Next Week In Biotech: Amgen, AbbVie, Biogen Earnings, UniQure CHMP, AAN Meeting
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
ABT: 48.32 (-0.14), BIIB: 401.71 (-28.57), NEO: 4.75 (-0.11), SGMO: 14.70 (-0.84), IMGN: 9.96 (-0.29), AMGN: 167.91 (-1.26), ILMN: 189.59 (-3.01), SVA: 5.10 (unch), BCLI: 4.14 (+0.02), ISRG: 505.92 (-6.85), BABY: 42.15 (-0.01), QURE: 26.09 (-0.28), NURO: 1.28 (-0.03), ABAX: 63.62 (+0.31), GWPH: 121.00 (+0.23), ALXN: 180.08 (-4.50), ABBV: 66.07 (+1.82), AMAG: 60.01 (-0.34), CAT: 84.60 (-0.19), MAA: 76.73 (-0.33), NVS: 104.28 (-1.22)

Can The Uptrend Continue for GW Pharmaceuticals (GWPH)?

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Heritage Wines Meet Non-Alcoholic Trend: New Deal

Wine Industry Shifts Gears Well, here's a twist that might just shake up the wine racks. C. Mondavi & Family, from the historic Charles Krug estate, is aligning with Missing Thorn—a name gaining traction in the non-alcoholic wine scene. It’s a move that not only raises eyebrows but could also expand your wine-tasting options come your next sober night out. So what...

J.H. Strain & Sons' Asset Sale Seals a New Era

Texan Legacy Bows Out of the Asphalt Game Here's a fresh chapter in the world of road construction that'll have folks in the industry doing a double-take. Elder Bray & Bankler, a bigwig among corporate law circles, has been guiding this tale. They've shepherded J.H. Strain & Sons through selling off its asphalt manufacturing and construction assets to none other than...

Instacart's Strong Q3 Amid DoorDash Acquisition News

Bumper Profits and Bold Moves for Instacart Here's a twist in the grocery tech aisle—Instacart's got some hefty numbers rolling in for Q3 and a whopper of an acquisition announcement. What seemed like just another Tuesday in the market is shaken by Instacart's reveal of their third-quarter financial results, showcasing a significant year-over-year climb that would make...

Army Embraces HAVIK Kits for Modern Fires Training

HAVIK Fires Into Army's Training Arsenal Well, folks, here we go again with some powerhouse corporate moves in the defense sector. The U.S. Army's grabbed a piece of HAVIK's pie, rolling out their ATLAS and SCOUT kits for their much-anticipated Fires simulation. Right off the bat, this isn't just another contract; it's a real game-changer in the Soldier Virtual Trainer...

TVC Group's Rebranding: Embracing Legacy, Eyeing Growth

TVC Group: A New Name, Same Trusted Legacy Here's a twist for anyone following the personal care market: The Village Company ditched its old name and popped out the shiny new 'TVC Group™'. It's all about waving the flag of evolution—keeping those consumer loyalties while sprucing up the corporate identity for the modern shelf-war era. Why the Name Change Actually...

Minesto Charts Bold Tides with Dragon Farms Funding

Minesto’s making waves, folks, and it ain’t just its tech splashing around. This Swedish tidal power ace is strutting on the global stage, flexing some serious muscle with projects that mean business. From the dragon-taming Faroe Islands to the Irish coasts, they’re pushing the envelope on tidal energy, and investors might wanna take note. Dragon Power Unleashed:...

Blade and Bow Drops Rare 30-Year-Old Cask Strength Expression

Turning Heads with a Rich Pour Forget watering down—Blade and Bow's latest masterpiece, the 30-Year-Old Cask Strength Kentucky Straight Bourbon Whiskey, is all about power. This new offering hasn't seen a drop of water since it left the barrel, clocking in at a punchy 164.2 proof. That's right, folks, they haven't pulled any punches this time. Heading into November,...

Florida 500 Honors Influential Health Leaders of 2026

Florida 500: Recognizing Impactful Leaders When it comes to shaking up the healthcare scene in Florida, John Couris and his crew are hardly treading water. Once again, Couris is rubbing elbows with the state's influential set, nabbing a spot on Florida Trend's 2026 "Florida 500" list. If you don't know, that's six years in a row. Those who've walked the grueling paths in...

Nelson Peltz Doubles Down: Burgers or Pucks?

Mixing Hockey and Hamburgers: The Peltz Way You'd think a guy like Nelson Peltz wouldn't be juggling hockey sticks and hamburgers at the same time, but here we are. The man, a mogul of sorts with Trian Fund Management, is hopping onto a board seat with a New York hockey company and, oh, by the way, throwing a non-binding $7.35-a-share cash proposal to snatch up Wendy's, a...

Meritus Health Adopts Sectra's Cloud for Radiology Boost

Meritus' Bold Move into the Cloud Jumping headlong into the tech game, Meritus Health has teamed up with Sectra to harness their One Cloud solution. This isn't just a plug-and-play deal; it's a strategic bet to overhaul how radiology is done. Do you know the kind of back-and-forth it takes to get a diagnostic image these days? Too much, if you ask me. Meritus is going...